Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Heart Failure: A Systematic Review
DOI:
https://doi.org/10.19166/med.v14i3.10164Λέξεις-κλειδιά:
Cardiovascular outcomes, Glucagon-like peptide-1 receptor agonists, Heart failure, SGLT2 inhibitorsΠερίληψη
Background: Heart failure (HF) affects over 64 million individuals globally and is associated with high morbidity and mortality, particularly in patients with type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging therapies with reported cardiovascular benefits. However, their comparative efficacy in HF-specific outcomes remains unclear. This systematic review aimed to assess and compare the safety and efficacy of SGLT2 inhibitors and GLP-1 RAs in patients with HF.
Methods: We systematically searched PubMed, EMBASE, and Scopus up to 1 May 2025 for randomized controlled trials (RCTs) evaluating SGLT2 inhibitors or GLP-1 RAs in adults with HF. Primary outcomes included all-cause and cardiovascular mortality; secondary outcomes included HF hospitalization and major adverse cardiovascular events (MACE). Risk of bias was assessed using the Cochrane RoB 2 tool and certainty of evidence with the GRADE approach.
Result: Fourteen RCTs comprising 30,867 patients (52.2% female; 63.2% with T2DM) were included. SGLT2 inhibitors significantly reduced cardiovascular mortality (RR: 0.85, 95% CI: 0.78–0.93, p < 0.001, I² = 14%), all-cause mortality (RR: 0.88, 95% CI: 0.81–0.95, p = 0.002, I² = 21%), and HF hospitalizations (RR: 0.72, 95% CI: 0.67–0.77, p < 0.001, I² = 0%). GLP-1 RAs did not demonstrate significant effects on these outcomes. Overall risk of bias was low to moderate; GRADE certainty ranged from moderate to high.
Conclusions: SGLT2 inhibitors provide consistent reductions in mortality and hospitalization in HF patients across glycemic statuses. GLP-1 RAs showed limited benefit in HF-specific outcomes, supporting the preferential use of SGLT2 inhibitors in HF treatment strategies.
Αναφορές
1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272–87. https://doi.org/10.1093/cvr/cvac013
2. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023 Oct;29(10):1412–51. https://doi.org/10.1016/j.cardfail.2023.07.006
3. Oktay AA, Paul TK, Koch CA, Lavie CJ. Diabetes, Cardiomyopathy, and Heart Failure. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2025 May 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK560257/
4. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020 Oct 8;383(15):1413–24. https://doi.org/10.1056/nejmoa2022190
5. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Oct 14;385(16):1451–61. https://doi.org/10.1056/nejmoa2107038
6. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995–2008. https://doi.org/10.1056/nejmoa1911303
7. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311–22. https://doi.org/10.1056/nejmoa1603827
8. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834–44. https://doi.org/10.1056/nejmoa1607141
9. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019 Aug 29;381(9):841–51. https://doi.org/10.1056/nejmoa1901118
10. Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled? Curr Heart Fail Rep. 2021 Oct;18(5):315–28. https://doi.org/10.1007/s11897-021-00529-8
11. Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209. https://doi.org/10.3389/fimmu.2023.1148209
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. https://doi.org/10.1136/bmj.n71
13. Solomon SD, McMurray JJV, Claggett B, De Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep 22;387(12):1089–98. https://doi.org/10.1056/nejmoa2206286
14. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117–28. https://doi.org/10.1056/nejmoa2030183
15. Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, et al. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2016 Jul;4(7):559–66. https://doi.org/10.1016/j.jchf.2016.01.008
16. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017 Jan;19(1):69–77. https://doi.org/10.1002/ejhf.657
17. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016 Aug 2;316(5):500. https://doi.org/10.1001/jama.2016.10260
18. Neves JS, Leite AR, Mentz RJ, Holman RR, Zannad F, Butler J, et al. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial. Eur J Heart Fail. 2025 Mar;27(3):540–51. https://doi.org/10.1002/ejhf.3478
19. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–29. https://doi.org/10.1016/s0140-6736(18)32261-x
20. Husain M, Bain SC, Jeppesen OK, Lingvay I, Sørrig R, Treppendahl MB, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020 Mar;22(3):442–51. https://doi.org/10.1111/dom.13955
21. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247–57. https://doi.org/10.1056/nejmoa1509225
22. Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 May 6]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK576405/
23. Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD. SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. J Lipid Atheroscler. 2022 Jan;11(1):1–19. https://doi.org/10.12997/jla.2022.11.1.1
24. Goedeke L, Ma Y, Gaspar RC, Nasiri A, Lee J, Zhang D, et al. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. J Clin Invest. 2024 Dec 16;134(24):e176708. https://doi.org/10.1172/jci176708
25. Blanco CA, Garcia K, Singson A, Smith WR. Use of SGLT2 Inhibitors Reduces Heart Failure and Hospitalization: A Multicenter, Real-World Evidence Study. Perm J. 2023 Mar 15;27(1):77–87. https://doi.org/10.7812/tpp/22.137
26. Dsouza G, Sharma M. NT-proBNP in Heart Failure with Preserved Ejection Fraction: A Comprehensive Review. Indian J Clin Cardiol. 2024 Dec;5(4):372–84. https://doi.org/10.1177/26324636241261422
Λήψεις
Δημοσιευμένα
Πώς να δημιουργήσετε Αναφορές
Τεύχος
Ενότητα
Άδεια
Πνευματική ιδιοκτησία (c) 2025 Evira Agustina Putri, Adinda Wafdani Putri, Andreago, Ariyani Sudhamma Welliangan, Vincent Guantoro, Harisa Mardiah
Αυτή η εργασία είναι αδειοδοτημένη υπό το Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
